INTRODUCTION
Atrial natriuretic factor (ANF), initially discovered by deBold et al. (1981) , is a peptide hormone that elicits multiple biological effects, which include diuresis, natriuresis, vasorelaxation and inhibition of aldosterone secretion (for reviews, see Ballerman & Brenner, 1985; Inagami, 1989) . ANF is produced in the atria (Kangawa et al. 1984; Thibault et al., 1987) as a 126-residue precursor (pro-ANF) and is processed to the major plasma circulating form, ANF-(99-126) (Thibault et al., 1985; Schwartz et al., 1985) . ANF is secreted by atrial cardiocytes into the bloodstream, where it travels to target tissues, such as kidney, adrenal gland and vascular smooth muscle, which contain specific high-affinity receptors (DeLean et al. 1984; Napier et al., 1984; Hori et al., 1985) . Many of the biological effects of ANF are believed to be mediated through the generation ofintracellular cyclic GMP via the stimulation of particulate guanylate cyclase (Hamet et al., 1984 (Hamet et al., , 1986 Waldman et al., 1984) . Multiple studies suggest that not all ANF receptor sites are coupled to the generation of cyclic GMP Scarborough et al., 1986; Takayanagi et al., 1987) , and Maack et al. (1987) have proposed that this non-coupled site functions to clear and store ANF.
The use of ANF as a therapeutic agent in various pathological conditions is limited since administration in vivo results in a very rapid clearance of the peptide from the circulation (half-lives of seconds to minutes) (Tang et al., 1984; Luft et al., 1986; Murthy et al., 1986a,b; Yandle et al., 1986) . Little is known about the processes that rapidly clear ANF from the bloodstream. Studies indicate that '25I-ANF binds to its receptor and is endocytosed in cultured smooth-muscle cells (Hirata et al., 1985; Napier et al., 1986; Johnson et al., 1989) . Proteolysis of ANF by purified kidney membranes (Koehn et al., 1987; Olins et al., 1987) , atrial tissue extracts (Harris & Wilson, 1984) and cultured smoothmuscle cells (Johnson et al., 1989) has been observed. An ectoenzyme of the renal brush border, endopeptidase-24.11, appears to be involved in the degradation and inactivation of ANF (Stephenson & Kenny, 1987; Kenny & Stephenson, 1988; Sonnenberg et al., 1988) . Although the kidney is a likely site for some of the degradation of ANF, animals in which the kidneys have been removed are still able to clear exogenously administered ANF rapidly (Luft et al., 1986; Murthy et al., 1986b) .
The goal of research in our laboratory is to understand better the metabolic fate of ANF in the vasculature using cell-culture models. We have previously studied the metabolism of radiolabelled ANF by cultured vascular smooth-muscle cells (Johnson et al., 1989) , and here we have studied the metabolism of radiolabelled ANF by cultured vascular endothelial cells so as to compare and contrast the ways these two types of cells process the radiolabelled hormone. Cultured bovine aortic endothelial cells (BAECs) are rich in high-affinity ANF receptor sites (Schenk et al., 1985; , although little is known about the metabolism of ANF by these cells. In the work described here, monoiodinated human ANF-(99-126) (1251-hANF) was added to the cells at a concentration of radiolabelled ANF near the physiological range (Ballerman & Brenner, 1985 degraded, resulting in the release of degradation products into the extracellular medium. Similarly to our findings with cultured smooth-muscle cells (Johnson et al., 1989) , the BAECs also produce a peptidase that removes the C-terminal tripeptide from '25I-hANF.
EXPERIMENTAL

Materials
The materials used in the experiments were the same as those described by Johnson et al. (1989) .
Preparation of iodinated standards
Arginyliodotyrosine and phenylalanylarginyliodotyrosine were prepared by the method of Johnson et al. (1989) . Cell culture BAECs were prepared as described by Schwartz (1978) 
RESULTS
NH4C1 and chloroquine inhibit the rapid clearance of 125I-hANF from the extracellular medium by cultured BAECs
The addition of 200 pM-251I-hANF (200fmol/well) to the cultured BAECs at 37°C resulted in a rapid clearance of the intact radiolabelled hormone from the extracellular medium (Fig. 1) . The half-life (ti) of this process was approx. 10 min (Fig. 1, *) . Preincubation and addition of 1251-hANF in the presence of 20 mM-NH4CI or 0.2 mM-chloroquine resulted in a significant inhibition of the clearance of 125I-hANF from the extracellular medium by BAECs ( [125I]iodotyrosine126 (125I-FRY). We have previously observed and identified these products being produced from 1251-hANF by cultured smooth-muscle cells (Johnson et al., 1989) . The small amounts of radiolabelled degradation products generated in these endothelial-cell assays (< 100 fmol) did not permit a direct characterization of these products by amino acid analysis or Edman degradation. However, knowing the position of the radiolabel in the 125I-hANF (C-terminal Tyr126) did allow us to confirm the identities of the degradation products generated by the BAECs. Retention times on analytical reverse-phase h.p.l.c. for these degradation products were not altered after reduction by 10 mM-dithiothreitol, indicating that all cleavages had occurred C-terminal to the disulphide bond formed between Cys105 and Cys121. The degradation products are co-eluted exactly with the synthetic standards iodotyrosine, arginyliodotyrosine and phenylalanylarginyliodotyrosine. Further, digestion of the putative 125I-FRY generated by endothelial cells with aminopeptidase M generated 125I-RY, followed by 1251-Y, whereas digestion of the putative 125I-RY only generated 1251_Y. 125I-Y was found to be insensitive to all exopeptidases and endopeptidases tested. These results clearly demonstrated that these products were derived from the C-terminal region of 125I-hANF and represent the C-terminal amino acid (1251-Y), dipeptide (125I-RY) and tripeptide (125I-FRY). It should also be noted that, in some h.p.l.c. analyses, we observed the production of two peaks with elution times of approx. 36 and 37 minutes (Fig. 2) . These peaks never accumulated to a large extent and in many analyses were not produced at all.
NH4C1 and chloroquine inhibit the generation of 1251-Y and 125I-RY, but not that of 125I-FRY Both 1251-Y (Fig. 3, *) and 125I-RY (Fig. 4, *) were released into the medium, and their quantity increased in a time-dependent fashion. These two degradation products were rapidly generated, and in 5 min had achieved 65 and 69 % of the maximal value for 125I-Y and 125I-RY respectively. The appearance of these radiolabelled degradation products in the extracellular medium was Furthermore, this inhibition was most dramatic in the first few minutes of the experiment. The C-terminal tripeptide, 125I-FRY, was found to be rapidly produced in the medium and its quantity decreased slightly as a function of time (Fig. 5, *) . In contrast with 125I-Y and 125I-RY, the amount of 1251I-FRY detected in the medium was not decreased when the cells were preincubated in 20 mM-NH4Cl or 0.2 mM-chloroquine (Fig. 5) .
'251-hANF binding to cell-surface receptors on BAECs Cell-surface-bound '25I-hANF was quantified by extracting the 1251-hANF from its receptor using 0.2 M-acetic acid/0.5 MNaCl for 6 min at 4°C (Haigler et al., 1980; Hirata et al., 1985; Johnson et al., 1989) . Non-specific binding of 125I-hANF (in the presence of excess unlabelled hANF) constituted approx. 10-15 % of total binding. The binding of 200 pM-125I-hANF to cell-surface receptors on BAECs at 37°C was very rapid, and within 2 min had achieved 73, 99 % and 93 % of the maximum value attained for control, NH4CI-treated and chloroquinetreated cells respectively (Fig. 6) . Fig. 6 demonstrates that the cells rapidly achieve a roughly steady-state amount of cellVol. 268 surface-bound 1251I-hANF, and this steady state is essentially maintained for the duration of the experiment. Preincubation of the cells in 0.2 mM-chloroquine increased the quantity of surfacebound 251I-hANF relative to control values and values obtained using cells preincubated in 20 mM-NH4Cl.
Receptor-mediated internalization of 1251-hANF by BAECs Internalized 251I-hANF was quantified as the residual cellbound radioactivity remaining after cell-surface-receptor-bound '25I-hANF had been removed (extracted) (Haigler et al., 1980; Hirata et al., 1985; Johnson et al., 1989) . Non-specific internalized '25I-hANF (in the presence of excess unlabelled hANF) represented approx. 20-30 % of total internalized 125I-hANF. As Fig.  7 shows (@, control values) , the amount of intracellular radiolabel increased in a time-dependent manner up to 5 min and then maintained a steady state for the duration of the experiment. Conversely, both NH4Cl and chloroquine induce a time-dependent increase in the intracellular accumulation of radiolabel throughout the duration of the experiment. Preincubation of the cells in 0.2 mM-chloroquine resulted in less intracellular radiolabel relative to control values in the first 10 min, whereas values attained after preincubation in 20 mM-NH4CI were roughly the same as control values attained in the first 10 min.
Excess unlabelled hANF blocks the rapid production of 1251-Y and 1251-RY, but not that of 1251-FRY To test the hypothesis that BAECs rapidly generate 125I-Y and 125I-RY from 125I-hANF by a receptor-mediated endocytotic intracellular degradative mechanism, the rapid degradation of 125I-hANF was monitored in the presence of excess unlabelled hANF. The excess (300 nM) unlabelled hANF was added to the cells to block the binding of the 200 pM-_21I-hANF to its receptor and thus block any degradative process that is mediated by the endocytosis of the receptor-ligand complex. As Table 1 shows, the presence of excess unlabelled hANF completely blocked (100% inhibition) the rapid production of 1251-Y and 125I-RY from 25I-hANF in the first 5 min. Conversely, the excess unlabelled hANF did not completely block the generation of the C-terminal tripeptide, 125I-FRY, from '25I-hANF, and only inhibited its production by 49 % (Table 1) . The inability to block the generation of 125I-FRY with excess unlabelled hANF indicates that it is generated via an extracellular proteolytic event.
DISCUSSION
The endothelium plays a crucial role in the metabolism of vasoactive peptides (Said, 1982) . The simultaneous analysis of Dean et al., 1984) . This increase in intravesicular pH can act to inhibit acid-dependent proteinases/peptidases within organelles such as lysosomes. There is also a large body of evidence indicating that weak bases inhibit the movement of receptors in cells (for a review, see Wileman et al., 1985) . The addition of excess unlabelled hANF was utilized to block binding of 125I-hANF to its receptor and thereby block degradative processes that were mediated via endocytosis of the receptor-ligand complex. Clearly, the finding that the rapid generation of 125I-Y and 125I-RY from 125I-hANF was inhibited by NH4C1, chloroquine and excess unlabelled hANF indicated that these degradation products were derived mostly from a receptor-mediated delivery and breakdown of 1251I-hANF at some intracellular site.
The generation of the C-terminal tripeptide, 1251-FRY, was not inhibited by NH4Cl and chloroquine, nor was its production completely blocked by excess unlabelled hANF. These observations demonstrate that the C-terminal tripeptide was generated by an extracellular proteolytic event and was not generated via a receptor-mediated endocytotic process. The fact that the amount of 1251I-FRY generated does not increase in a time-dependent fashion suggests that the tripeptide is being degraded to some extent at later time points. We have previously observed the extracellular generation of the C-terminal tripeptide from 251I-hANF by cultured smooth-muscle cells (Johnson et al. 1989) . A peptidase with this specificity is of particular interest, since the presence of the Phe124-Arg125-Tyr126 residues in ANF are necessary to generate cyclic GMP in cultured vascular smoothmuscle (Scarborough et al., 1986 ) and endothelial cells . (Stephenson & Kenny, 1987) and atrial dipeptidyl carboxyhydrolase (Harris & Wilson, 1984; Soler & Harris, 1989) catalyse the hydrolysis of the Ser123-Phe124 bond of ANF. These enzymes are not responsible for the activity that we observed, since inclusion of 100 pM-SCH 39370, an endopeptidase-24.11 inhibitor (Haslanger et al., 1989) or of 10 ,/M-captopril, an atrial dipeptidyl carboxyhydrolase (and angiotensin-converting-enzyme) inhibitor, (Harris & Wilson, 1984) (Wileman et al., 1985) . The results of our experiments suggest that hANF receptors in endothelial cells recycle between intracellular stores and the cell surface, either in the presence and/or absence of ligand. The fact that NH4Cl, chloroquine and excess unlabelled hANF inhibit an endocytotic/degradative process that occurs so rapidly (within minutes after the addition of '251-hANF) suggests the involvement of early endosomes, since receptor recycling via early endosomes occurs with halftimes of less than 3 min (Ciechanover et al., 1983; Klausner et al., 1983; Townsend et al., 1984) , while half-times for the delivery of ligands from endosomes to lysosomes are often slow (30-60 min) (Wolkoff et al., 1984; Wall & Hubbard, 1985; Dunn et al., 1986 ).
In conclusion, cultured endothelial cells rapidly degrade 1251_ hANF into three predominant products derived from its Cterminal region, 1251-Y, '251-RY and 251I-FRY. Two of these products, 1251-Y and 125I-RY, are rapidly generated via a receptormediated endocytotic process and intracellular breakdown, whereas the third, 125I-FRY, is produced by an extracellular proteolytic event. The rapid metabolism of 251I-hANF in this cell-culture model of the endothelium may provide additional insight into the mechanisms by which hANF is rapidly metabolized in vivo.
